Cardiomyopathy Associated with Diabetes: The Central Role of the Cardiomyocyte

International Journal of Molecular Sciences

Gaetano Tanzilli¹  Tiziana Filardi²  Susanna Morano²  Andrea Lenzi²  Barbara Ghinassi³  Angela Di Baldassarre³  Clara Crescioli⁴  Stefania Basili⁵ 

[1] Department of Cardiovascular Sciences, “Sapienza” University, Viale del Policlinico 155, 00161 Rome, Italy;Department of Experimental Medicine, “Sapienza” University, Viale del Policlinico 155, 00161 Rome, Italy;Department of Medicine and Aging Sciences, “G. D’Annunzio” University of Chieti and Pescara, Via dei Vestini 31, 66100 Chieti, Italy;Department of Movement, Human and Health Sciences, Section of Health Sciences, University of Rome “Foro Italico”, Piazza L. de Bosis 6, 00135 Rome, Italy;Department of Translational and Precision Medicine, “Sapienza” University of Rome, Viale del Policlinico 155, 00161 Rome, Italy;

关键词: diabetes;    cardiomyopathy;    cardiomyocytes;    chemokines;    inflammation;    therapy;   

DOI  :  10.3390/ijms20133299

来源: DOAJ

【 摘 要 】

The term diabetic cardiomyopathy (DCM) labels an abnormal cardiac structure and performance due to intrinsic heart muscle malfunction, independently of other vascular co-morbidity. DCM, accounting for 50%–80% of deaths in diabetic patients, represents a worldwide problem for human health and related economics. Optimal glycemic control is not sufficient to prevent DCM, which derives from heart remodeling and geometrical changes, with both consequences of critical events initially occurring at the cardiomyocyte level. Cardiac cells, under hyperglycemia, very early undergo metabolic abnormalities and contribute to T helper (Th)-driven inflammatory perturbation, behaving as immunoactive units capable of releasing critical biomediators, such as cytokines and chemokines. This paper aims to focus onto the role of cardiomyocytes, no longer considered as “passive” targets but as “active” units participating in the inflammatory dialogue between local and systemic counterparts underlying DCM development and maintenance. Some of the main biomolecular/metabolic/inflammatory processes triggered within cardiac cells by high glucose are overviewed; particular attention is addressed to early inflammatory cytokines and chemokines, representing potential therapeutic targets for a prompt early intervention when no signs or symptoms of DCM are manifesting yet. DCM clinical management still represents a challenge and further translational investigations, including studies at female/male cell level, are warranted.

【 授权许可】

Unknown